Researchers Seek Vaccine to Treat Widespread Parasitic Disease
A new article in The Journal of Parasitology features a study on schistosomiasis vaccine research. The researchers hypothesized that attacking ESP-induced immune responses would lead to almost total elimination of the parasite.
Lawrence, KS (PRWEB) April 25, 2013
Nearly 800 million people, mostly children, are at risk for schistosomiasis, a widespread parasitic disease found in more than 75 developing countries. Although drug treatment is effective, it does not prevent reinfection. Research is now progressing toward a schistosomiasis vaccine in the foreseeable future.
An article featured in The Journal of Parasitology reports test results of immunization combinations in mice. Researchers are seeking the correct vaccine antigen that will ensure effective immunization against this parasite.
Snails can carry this parasite to humans, typically in places lacking water sanitation facilities. Although mortality is low, schistosomiasis can cause progressive liver or urinary bladder tissue damage. Subsequent infections can be more severe after a first exposure to schistosomiasis.
The drug praziquantel has been effective in killing this parasite. However, it does not prevent infection, and there is concern that the parasite will develop resistance to the drug, which is now in widespread use. A vaccine is needed.
Looking for the correct antigen, researchers in the current study focused on excretory-secretory products (ESP) of the Schistosoma mansoni parasite. These products are released during the early and later stages of infection. The researchers hypothesized that attacking ESP-induced immune responses would lead to almost total elimination of the parasite.
In the current study, the researchers first immunized mice and two weeks later exposed the mice to the parasite. Six experiments consistently showed a highly significant 62 percent to 78 percent reduction in challenge worm burden compared to untreated controls.
These experiments have shown consistent, reproducible results in repeated tests. The next steps toward a schistosomiasis vaccine should be to clarify the molecular basis of protection and move toward production of the antigen, independent trials, and preclinical and clinical studies.
Full text of “Vaccine-induced Protection Against Murine Schistomiasis Mansoni with Larval Excretory-Secretory Antigens and Papain or Type-2 Cytokines,” The Journal of Parasitology, Vol. 99, No. 2, 2013, is now available.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10672685.htm